Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
Lineage Cell Therapeutics, Inc.
| Metric | Lineage Cell Therapeutics, Inc. LCTXHealthcare |
|---|---|
| Quality Score | 57 / 100 |
| Revenue (latest) | $15M |
| Net income (latest) | −$64M |
| Operating margin | −251.6% |
| Net margin | −436.5% |
| Return on equity | −142.6% |
| Return on assets | −56.4% |
| Return on capital (ROCE) | −36.2% |
| Debt / equity | 1.55× |
| Revenue growth (YoY) | 53.2% |
| Altman Z″ (distress) | -12.25 |
| Accruals / assets | −39.6% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.